Cathepsin L Inhibitor (Z-FY-CHO)
(Synonyms: SB 412515; Z-FY-CHO) 目录号 : GC18498
Cathepsin L Inhibitor (Z-FY-CHO)是一种能够特异性抑制Cathepsin L活性的化合物(Ki=0.185nM),用于研究Cathepsin L在细胞内溶酶体功能和蛋白质降解过程中的作用。
Cas No.:167498-29-5
Sample solution is provided at 25 µL, 10mM.
Cathepsin L Inhibitor (Z-FY-CHO) is a compound that can specifically inhibit the activity of Cathepsin L (Ki = 0.185nM) and is used to study the role of Cathepsin L in lysosomal function and protein degradation within cells[1]. Cathepsin L Inhibitor can bind to the active site of Cathepsin L, preventing its hydrolytic action on substrates, thereby regulating the metabolic balance of proteins within the cell[2]. Cathepsin L Inhibitor can be used to study the mechanisms of action of Cathepsin L in autophagy, apoptosis, and signal transduction in cells, helping to reveal the functions of Cathepsin L in physiological and pathological processes[3]. Cathepsin L Inhibitor also has potential anti-tumor effects, inhibiting the invasion and metastasis of tumor cells[4].
In vitro, pre-treatment of prostate cancer cells (LNCaP, C4-2) with Cathepsin L Inhibitor (5μM) for 30 minutes to 48 hours significantly inhibits cell migration and proliferation, while reducing STAT3 phosphorylation and Snail expression[5]. Pre-treatment of prostate cancer cells (ARCaP-M, ARCaP-Snail) and breast cancer cells (MDA-MB-468, MCF-7) with Cathepsin L Inhibitor (1–20μM) for 72 hours significantly inhibits the expression of Snail and vimentin, while restoring the expression of E-cadherin, inducing mesenchymal-to-epithelial transition (MET), and reducing cell migration and invasion capabilities[6].
In vivo, daily intraperitoneal injection of Cathepsin L Inhibitor (2.5–10mg/kg) in ovariectomized mice for 4 weeks significantly inhibits bone weight loss and reduces hydroxyproline content, while inhibiting collagen degradation[7]. Daily intraperitoneal injection of Cathepsin L Inhibitor (5mg/kg) in DSS-induced colitis mice for 7 days significantly alleviates body weight loss, colon shortening, and histological scores in colitis mice, while improving inflammatory symptoms[8].
References:
[1] Wiener JJ, Sun S, Thurmond RL. Recent advances in the design of cathepsin S inhibitors. Curr Top Med Chem. 2010;10(7):717-32.
[2] Burton LJ, Smith BA, Smith BN, et al. Muscadine grape skin extract can antagonize Snail-cathepsin L-mediated invasion, migration and osteoclastogenesis in prostate and breast cancer cells. Carcinogenesis. 2015 Sep;36(9):1019-27.
[3] Li L, Gao L, Song Y, et al. Activated cathepsin L is associated with the switch from autophagy to apoptotic death of SH-SY5Y cells exposed to 6-hydroxydopamine. Biochem Biophys Res Commun. 2016 Feb 12;470(3):579-585.
[4] Xiong Y, Ji W, Fei Y, et al. Cathepsin L is involved in X-ray-induced invasion and migration of human glioma U251 cells. Cell Signal. 2017 Jan;29:181-191.
[5] Henderson VM, Hawsawi O, Burton LJ, et al. Cancer-bone microenvironmental interactions promotes STAT3 signaling. Mol Carcinog. 2019 Aug;58(8):1349-1361.
[6] Burton LJ, Dougan J, Jones J, et al. Targeting the Nuclear Cathepsin L CCAAT Displacement Protein/Cut Homeobox Transcription Factor-Epithelial Mesenchymal Transition Pathway in Prostate and Breast Cancer Cells with the Z-FY-CHO Inhibitor. Mol Cell Biol. 2017 Feb 15;37(5):e00297-16.
[7] Woo JT, Yamaguchi K, Hayama T, et al. Suppressive effect of N-(benzyloxycarbonyl)-L-phenylalanyl-L-tyrosinal on bone resorption in vitro and in vivo. Eur J Pharmacol. 1996 Apr 4;300(1-2):131-5.
[8] Menzel K, Hausmann M, Obermeier F, et al. Cathepsins B, L and D in inflammatory bowel disease macrophages and potential therapeutic effects of cathepsin inhibition in vivo. Clin Exp Immunol. 2006 Oct;146(1):169-80.
Cathepsin L Inhibitor (Z-FY-CHO)是一种能够特异性抑制Cathepsin L活性的化合物(Ki=0.185nM),用于研究Cathepsin L在细胞内溶酶体功能和蛋白质降解过程中的作用[1]。Cathepsin L Inhibitor可以与Cathepsin L的活性位点结合,阻止其对底物的水解作用,从而调节细胞内蛋白质的代谢平衡[2]。Cathepsin L Inhibitor可用于研究Cathepsin L在细胞自噬、细胞凋亡以及细胞信号传导中的作用机制,帮助揭示Cathepsin L在细胞生理和病理过程中的功能[3]。Cathepsin L Inhibitor还具有潜在的抗肿瘤作用,可抑制肿瘤细胞的侵袭和转移[4]。
在体外,Cathepsin L Inhibitor(5μM)预处理前列腺癌细胞(LNCaP、C4-2)30分钟至48小时,Cathepsin L Inhibitor显著抑制细胞迁移和增殖,同时降低STAT3磷酸化及Snail表达[5]。Cathepsin L Inhibitor(1–20μM)预处理前列腺癌细胞(ARCaP-M、ARCaP-Snail)及乳腺癌细胞(MDA-MB-468、MCF-7)72小时,Cathepsin L Inhibitor显著抑制Snail和波形蛋白(Vimentin)的表达,同时恢复E-钙黏蛋白(E-cadherin)的表达,诱导间质-上皮转化(MET),并降低细胞迁移和侵袭能力[6]。
在体内,Cathepsin L Inhibitor(2.5–10mg/kg)每日腹腔注射处理卵巢切除小鼠4周,显著抑制骨重量损失和羟基脯氨酸含量降低,同时抑制胶原降解[7]。Cathepsin L Inhibitor(5mg/kg)每日腹腔注射处理DSS诱导结肠炎小鼠7天,Cathepsin L Inhibitor显著减轻结肠炎小鼠体重下降、结肠缩短和组织学评分,同时改善炎症症状[8]。
| Cell experiment [1]: | |
Cell lines | LNCaP cells (human prostate cancer cell line), C4-2 cells (human prostate cancer cell line) |
Preparation Method | LNCaP and C4-2 cells were maintained in RPMI or DMEM media supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37°C, 5% CO₂. Cells were treated with conditioned media (CM) from co-cultures of prostate cancer cells with hydroxyapatite (HA) in the presence or absence of Cathepsin L Inhibitor (5μM) for various time points. |
Reaction Conditions | 5μM; 5min to 48h |
Applications | Cathepsin L Inhibitor significantly inhibited paracrine STAT3 phosphorylation, cell proliferation, and migration induced by cancer-bone microenvironment interactions. Cathepsin L Inhibitor abrogated the increase in calcium-mediated signaling and Snail expression. |
| Animal experiment [2]: | |
Animal models | Ovariectomized ddY mice (experimental model of osteoporosis) |
Preparation Method | Mice were intraperitoneally administered Cathepsin L Inhibitor (2.5-10mg/kg/day) dissolved in 5% dimethylsulfoxide daily for 4 weeks starting from the day of operation. Mice were sacrificed 4 weeks after ovariectomy for femur analysis. |
Dosage form | 2.5-10mg/kg/day; i.p. |
Applications | Cathepsin L Inhibitor administration significantly suppressed bone weight loss and reduced hydroxyproline content decrease in femurs of ovariectomized mice in a dose-dependent manner, indicating inhibition of bone collagen degradation and osteoclastic bone resorption. |
References: | |
| Cas No. | 167498-29-5 | SDF | |
| 别名 | SB 412515; Z-FY-CHO | ||
| 化学名 | N-[(1S)-2-[[(1S)-1-formyl-2-(4-hydroxyphenyl)ethyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-carbamic acid, phenylmethyl ester | ||
| Canonical SMILES | OC1=CC=C(C[C@@H](C=O)NC([C@H](CC2=CC=CC=C2)NC(OCC3=CC=CC=C3)=O)=O)C=C1 | ||
| 分子式 | C26H26N2O5 | 分子量 | 446.5 |
| 溶解度 | 20 mg/ml in DMSO, 20 mg/ml in DMF, 2 mg/ml in Ethanol | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2396 mL | 11.1982 mL | 22.3964 mL |
| 5 mM | 447.9 μL | 2.2396 mL | 4.4793 mL |
| 10 mM | 224 μL | 1.1198 mL | 2.2396 mL |
| 第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
| 给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
| 第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
















